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1 INTRODUCTION 
1.1 Living donor liver transplantation using small-for-size grafts 
Living donor liver transplantation (LDLT), using a relative or another person closely 
related to the recipient as a donor, was theoretically proposed by Smith in 1969 to 
alleviate the critical shortage of cadaveric graft supply for children (Smith, 1969). 
In 1989, it was introduced into clinical reality with the first successful series of 
paediatric recipients by Broelsch (Broelsch et al., 1991).  
The success in paediatric liver transplantation and a refined surgical technique led 
to the adaptation of LDLT for adults (Marcos et al., 1999). Since then, LDLT has 
become a generally accepted procedure with a relevant impact on the treatment of 
end-stage liver diseases. The major indications expanded from biliary atresia and 
other paediatric liver diseases to a variety of liver diseases occurring in adults, 
particularly hepatocellular carcinoma (HCC) and hepatitis B-related liver cirrhosis 
(Tanaka, 2003). The applicability in terms of timing of surgery has been extended 
from elective to highly urgent transplants for fulminant, subacute, and acute-on-
chronic liver failure (Chen et al., 2003). Up to date, the annual number of LDLT 
has rapidly increased in Germany since 1997, and it accounts for more than 10% 
of all liver transplantations (Figure 1). The trend of the greater applicability of LDLT 
in North America is similar to that seen in Germany (Renz et al., 2003).  
However, LDLT requires the use of a partial liver graft, which is small-for-size 
when transplanted to an adult. Lo considered that the reduced size was a 
dominant factor contributing to impaired postoperative graft function (Lo et al., 
1996), indicating that using a small-for-size graft in adult-to-adult LDLT remains a 
problem. The minimal graft volume required to meet the metabolic and 
regenerative demand of the recipient is undefined till now. There is general 
agreement that the lower limit depends on the recipient’s condition, the quality of 
the graft as well as the technique of transplantation performed (Broering et al., 
2003). The graft-to-recipient weight ratio (GRWR) or graft-to-recipient standard 
liver volume ratio (GSLV) of the recipient has been used to determine the ideal 
liver volume for recipients.  A GRWR of 0.8-1% or a GSLV of 40-50% are 
considered safe (Nishizaki et al., 2001).  
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Compared to other organs, the liver has the unique capacity to regenerate and 
adjust its size according to the requirement of the host  (Francavilla et al., 1994a). 
Therefore, liver regeneration is a very critical factor to the success of LDLT.  
 
 
 
1.2 Liver regeneration after hepatectomy and partial liver transplantation 
1.2.1 Basic characteristics of liver regeneration  
Liver regeneration has long been recognized, as implied by the ancient Greek 
myth of Prometheus. Having stolen the secret of fire from the gods of Olympus, 
Prometheus was condemned to having a portion of his liver eaten daily by an 
eagle. His liver regenerated overnight, thus providing the eagle with eternal food 
and Prometheus with eternal torture (Figure 2).  
In modern times, liver regeneration is described as the remarkable capacity to 
reestablish its optimal volume in relation to body size after injury and cell loss 
through DNA synthesis and mitosis (Court FG et al., 2002). The most commonly 
studied model is the 70% partial hepatectomy (PH) in rodents which was 
introduced by Higgins and Anderson (Higgins GM et al.,1931). After PH, the 
Figure 1. Annual number of LDLT cases in Germany. 
(Deutsche Stiftung Organtransplantation. www.dso.de) 
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residual liver lobes enlarge to make up for the mass of the removed lobes until the 
original size has been restored. Once this has been attained, liver regeneration 
halts abruptly (Steer, 1995).  The whole process, which lasts 7 to 10 days in rats, 
is compensatory because the size of the resultant liver is determined by the 
demands of the organism.  
 
 
1.2.2 Factors influencing liver regeneration  
In liver resection and in partial liver transplantation, regeneration is essential to 
restore an adequate liver size. Regeneration of the liver can be affected by a 
variety of factors. First of all, it depends on the volume of remnant or transplanted 
liver and the original liver volume of the patient. The extent of regeneration 
following PH is directly correlated to the extent of liver mass reduction (Masson et 
al., 1999). In addition, the quality of the remnant or grafted liver is of special 
concern, e.g. steatosis has been shown to reduce the rate of hepatic regeneration 
after resection (Selzner and Clavien, 2000).  
Ischemia-reperfusion injury is the unavoidable damage specific to the 
transplantation procedures (Selzner et al., 2002b), which may affect the 
regeneration process as well. A poor general condition of the recipient as well as 
Figure 2. Liver regeneration and the legend of Prometheus. 
                  (Copied from www.the-pantheon.com)  
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postoperative complications may also influence the regenerative capacity of the 
graft (Shiffman et al., 2002).  
LDLT between adults results in a small-for-size hepatic graft, which in general is 
subjected to shorter period of cold ischemia than a cadaveric graft. However, the 
graft needs to regenerate to accommodate the recipient’s metabolic requirements. 
Therefore, it is essential to determine the influence of the transplantation 
procedure itself as well as the effect of prolonged cold ischemia on the process of 
liver regeneration.  
1.2.3 Immunological regulation of liver regeneration 
Recently a feedback mechanism regarding the regulation of liver regeneration was 
postulated (Dahmen and Dirsch, 2002). It was hypothesized that liver regeneration 
and immune activation are inversely related.  
1. Regeneration is inducing a general immune activation.  
2. Immune activation is inhibiting regeneration.  
=> Inhibition of immune activation is enhancing the regenerative response. 
1.2.3.1 Influence of immune activation   
This postulated mechanism might be of special importance when using small-for-
size liver grafts in patients transplanted for chronic viral liver disease. Viral 
hepatitis leads to an ongoing immune activation potentially sufficient to impair 
regeneration. This question can be best addressed in a surrogate model, such as 
observing liver regeneration after PH in animals undergoing Hepatitis B 
vaccination.  
1.2.3.2 Effect of inhibiting immune activation  
Patients after liver transplantation are always subjected to immunosuppressive 
therapy to inhibit the immunologic attack of the graft by the recipient immune 
system. In general a combination therapy is used, seeking to inhibit T cell 
activation by blocking the interleukin-2 (IL-2) pathway as well as inhibiting T cell 
proliferation (Tanaka et al., 1993e).  
Assessing liver regeneration under the influence of single immunosuppressive 
drug acting differently on the immune response may help to elucidate how 
inhibition of immune activation can enhance regeneration.  
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1.3 Methods for assessing liver regeneration 
Liver regeneration can be assessed by a number of tissue-based tests and various 
serum-based methods. The former includes liver weights, mitotic counts, DNA 
synthesis rates, immunohistochemical staining of nuclear antigens, gene 
expressions and certain protein levels. The latter one mainly consists of specific 
enzyme determinations such as thymidine kinase or documentation of certain 
proliferation markers.  
Measurement of liver weight is the simplest tissue-based test. However, this 
determination may be influenced by oedematous swelling of the liver subsequent 
to resection and, as Assy suggested, by the deposition of various materials such 
as lipid and glycogen (Assy and Minuk, 1997b). The determination of mitotic 
figures can result in artificially low counts because mitosis may proceed to 
completion in inadequately fixed tissue samples while new mitotic figures do not 
develop (Baak, 1990). 3H-thymidine and Bromodeoxyuridine (BrdU) incorporation 
into DNA are the reference tools for studying DNA synthesis, but their use requires 
pre-injection with radioactive isotope-labelled or halogenated nucleotides (Baratta 
et al., 1996). Immunohistochemical staining for nuclear antigens including Ki-67, 
proliferating cell nuclear antigen (PCNA), DNA polymerase alpha and nucleolar 
organizer region (NOR) proteins are acceptable and commonly used methods but 
the antigens in question are expressed in various phases of the cell cycle (Assy 
and Minuk, 1997a).  
Of the serum-based determinations, thymidine kinase (TK), ornithine 
decarboxylase (ODC), fibronectin, alpha fetoprotein and early pregnancy factor 
offer practical and non-invasive tools to monitor liver regeneration, but their 
sensitivity and specificity have yet to be determined (Assy and Minuk, 1997c). 
Although there are disadvantages inherent in each method, the gold standard has 
long been the in vivo labelling of DNA by the modified pyrimidine analogue , a 
halogenated derivative of thymidine, BrdU (Gratzner, 1982; Muskhelishvili et al., 
2003). It is readily incorporated into nuclei during the DNA synthetic phase of the 
cell cycle and is detected by immunohistochemistry (IHC) with anti-BrdU antibody. 
It combines the advantages of speed and technical simplicity and it doesn’t require 
exposure to radioactive materials or sophisticated equipment. Thus, determination 
of BrdU incorporation has been proven to be a powerful parameter in the study of 
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proliferating cells (Abbasoglu et al., 1995; Miyagawa et al., 1997; Tarao et al., 
1991).  
As BrdU incorporation is frequently used to assess liver regeneration in 
experimental models, a variety of different protocols exist regarding the application 
route and time as well as regarding the immunohistochemical assay. Furthermore, 
also the evaluation method is subjected to a considerable variability. The results 
may be given as positive cells irrespectively of cell type/high power field or positive 
cells of a given type/given number of total cells.  Additional variation of the results 
may be related to inter- and intra- observer variability. Validation of the 
immunohistochemical assay is therefore considered indispensable prior to a 
quantitative evaluation. 
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1.4 Aim of this study 
Living liver donation between adults requires an extended resection in the donor to 
obtain a small-for-size graft for the recipient. This decrease in functional liver mass 
puts the recipient at risk of transient liver insufficiency. Only regeneration of the 
liver can restore an adequate functional liver mass.  
This animal experiment was designed to investigate liver regeneration after 
hepatectomy and small-for-size liver transplantation from living donors using rat 
models.   
 
1. Liver regeneration was assessed using the BrdU incorporation method. Interest 
was focused on the validation of the quantification method and the 
immunohistochemical assay by  
a. Comparing conventional and computer-assisted counting  
b. Determining the assay precision of BrdU-IHC staining 
 
2. Liver regeneration after transplantation was studied by investigating  
a. Kinetics of regeneration after small-for-size liver transplantation  
b. Influence of extended cold ischemia on regeneration of a small-for-size graft 
 
3. The feedback mechanism between liver regeneration and immune activation 
was studied using liver resection as a surrogate model. Special attention was 
given to study the effect of  
a. Immune activation by vaccination on liver regeneration  
b. Inhibition of immune activation by immunosuppressive drugs 
· Inhibition of IL-2 activation (cyclosporine A (CsA), FK506) 
· Inhibition of T cell proliferation (mycophenolate mofetil (MMF) and 
Sirolimus (RAD)) 
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2 MATERIALS AND METHODS 
2.1 Experimental design 
This experiment was designed to investigate liver regeneration after liver resection 
and small-for-size liver transplantation from living donor using the rat models. The 
regenerative capacity was evaluated by BrdU incorporation method. Accordingly, 
the control and experimental groups were set up as follows: 
2.1.1 Control groups 
a. Naive group (n=10) 
b. 70%PH group (n=24, 6 animals from each subgroup were sacrificed at 24, 
48, 72 hours and 1 week after 70%PH) 
c. 90%PH group (n=8, animals were sacrificed at 48 hours after 90%PH) 
2.1.2 Experimental groups 
The various experimental groups were designed to answer the following questions: 
a. Kinetics of regeneration after small-for-size liver transplantation. 
30% nonarterialized partial orthotopic liver transplantation (NAPOLT) was 
performed in a syngeneic strain combination (Lewis to Lewis). The corresponding 
course of regeneration was compared with that after 70%PH. 6 animals from each 
subgroup were sacrificed at 24, 48, 72 hours and 1 week after transplantation 
(Table 1). 
 
Table 1. Experimental design for investigating the regeneration kinetics after 
small-for-size liver transplantation 
Observation Periods Group 
24 hours 48 hours 72 hours 1 week 
70%PH (n=6) (n=6) (n=6) (n=6) 
30%NAPOLT (n=6) (n=6) (n=6) (n=6) 
 
 
b. Influence of duration of cold ischemia on regeneration of a small-for-size 
graft. 
30%NAPOLT was performed in a syngeneic strain combination (Lewis to Lewis). 
Cold ischemic time of the graft was set to 1, 3 and 5 hours, respectively. In order 
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to assess the influence of prolonged ischemia on outcome the 1-week survival rate 
was assessed. The influence of prolonged ischemia on proliferation rates was 
assessed at 48h postoperatively and compared with those after 70%PH (Table 2). 
 
Table 2.  Experimental design for investigating the influence of prolonged cold 
ischemia on liver regeneration of a small-for-size graft 
Group Ischemic time 1-week 
survival rate 
Proliferation rate  
(48h postoperatively) 
70%PH Control  (n=6) (n=6) 
1 hour  (n=6) (n=6) 
3 hours  (n=10) (n=4) 30%NAPOLT 
5 hours  (n=10) (n=3) 
 
 
c. Immune activation by vaccination on liver regeneration. 
Vaccination with hepatitis B vaccine can induce immune activation in vivo (Keating 
and Noble, 2003). Thus, the influence of immune activation on liver regeneration 
was tested by stimulating the animal 7 days prior to 70%PH by vaccination, which 
was used as a surrogate model of small-for-size partial liver transplantation. The 
proliferation rate at 24, 48, 72 hours and 1 week postoperative were observed 
(Table 3). 
 
Table 3. Experimental design for exploring the influence of immune activation by 
vaccination on liver regeneration 
Observation Periods Group 
24 hours 48 hours 72 hours 1 week 
70%PH-control (n=6) (n=6) (n=6) (n=6) 
70%PH-vaccinated (n=6) (n=6) (n=6) (n=6) 
 
 
d. Inhibition of immune activation by immunosuppressive drugs. 
Subtotal resection was performed as a surrogate model to evaluate the 
regenerative ability of small-for-size graft treated with immunosuppressive drugs. 
32 animals were divided into 4 groups. 8 animals in each group were treated with 
CsA, FK506, MMF and RAD respectively one day prior to 90%PH. Proliferation 
rate at 48 hours postoperatively was observed (Table 4). 
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Table 4. Experimental design for investigating the influence of immunosuppressive 
drugs on liver regeneration 
Operation Observation time point Treatment 
Control (n=8) 
CsA (n=8) 
FK506 (n=8) 
MMF (n=8) 
90%PH 
48 hours 
postoperatively 
 
RAD (n=8) 
       
2.2 Animals 
Experiments were performed in inbred male Lewis (LEW, RT1 l) rats (Figure 3) 
weighing 250 to 350g, which were obtained from Charles River Gmbh (Sulzfeld, 
Germany). Donor and recipient rats of similar weight (+/-10g) were chosen 
randomly. The animals were housed under standard animal care conditions and 
fed with standard rat chow (Rat Food 10H10, Firma Nohrlin, Germany) ad libitum 
before and after operations. Surgical procedures were done mainly under isofluran 
(CuraMed Pharma GmbH, Karlsruhe, Germany) anesthesia. The rats were 
maintained behind barriers under controlled environmental conditions. Animal 
housing and procedures were carried out according to the German Animal Welfare 
Legislation. 
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Figure 3.  Experiment animal: inbred male Lewis rat 
RM                LM                    
RLS 
RLI                   
L
L 
C
L 
30% 
70%PH 
10% 
90%P
H 
30% 
30%NAPOL
T 
Figure 4. Partial hepatectomy and nonarterialized partial orthotopic liver 
transplantation (NAPOLT). The rat liver consists of right portion and left 
portion of median lobe (RM and LM), superior and inferior portion of right 
lateral lobe (RLS and RLI), left lateral lobe (LL), anterior and posterior 
caudate lobe (CLA and CLP). The green portion indicates the remnant 
liver after partial hepatectomy (left and middle) and the liver lobes forming 
the 30% graft volume (right) in NAPOLT. 
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2.3 Operations 
2.3.1 Partial hepatectomy 
Partial hepatectomy was performed according to the technique of Higgins’ 
(Higgins GM et al.,1931). Briefly, the median lobe and left lateral lobe were 
resected for a 70%PH while the median lobe, left lateral lobe and right lateral lobe 
were resected for a 90%PH (Figure 4). 
2.3.2 Nonarterialized small-for-size orthotopic liver transplantation  
Orthotopic liver transplantation was performed according to the cuff technique of 
Kamada and Calne (Kamada and Calne, 1983). Graft reduction was performed in 
situ prior to perfusion of the graft with physiological saline. The 30% graft that 
included the superior and inferior portion of the right lateral lobe (RLS and RLI) 
and the caudate lobe (CL) were stored at 4°C for either 1 hour, 3 hours or 5 hours 
before implantation (Figure 4). 
2.4 Treatment 
2.4.1 Standard perioperative treatment 
All animals were treated immediately with 100 mg/kg/d Mezlocillin (Baypen, Bayer 
AG, Leverkusen, Germany) by intramuscular injection after the operation. 
2.4.2 Glucose supplementation 
A dose of 5ml 10% glucose solution (Fresenius, Germany) was injected 
subcutaneously immediately after operation. Besides normal tap water, 20% 
glucose solution (Fresenius, Germany) was supplied for drinking for 3 days after 
90%PH and after 30%NAPOLT. 
2.4.3 Vaccination 
Recombinant hepatitis B Vaccine ENGERIX -B (20mcg/1ml, GlaxoSmithKlein 
Biologicals, Rixensart, Belgium) was administered intramuscularly in a dose of 
0.2ml 7 days prior to 70%PH. 
2.4.4 Immunosuppressive treatment 
Animals received one of the following 4 immunosuppressive drugs one day prior to 
90%PH: CsA (5mg/kg/d, subcutaneously, SandimmuneTM, Novartis, Switzerland), 
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FK506 (1mg/kg/d, subcutaneously, PrografTM, Fujisawa, Japan), MMF (40mg/kg/d, 
subcutaneously, CellCeptTM, Roche, Switzerland) or RAD (2.5  mg/kg/d, by gavage, 
obtained directly from Novartis, Switzerland). 
2.5 Sampling of animals 
Animals were injected with BrdU (Sigma Inc, USA. 50mg/kg body weight, 
dissolved in 1.0 ml of 0.9% sodium chloride solution) intravenously one hour 
before sacrifice, followed by laparotomy under anesthesia. After complete 
inspection of the abdominal cavity to detect surgical complications, liver tissue was 
removed and fixed in 10% buffered formalin for immunohistochemical staining. 
2.6 Evaluation of liver regeneration 
2.6.1 Immunohistochemical staining of BrdU 
Incorporated BrdU was detected by immunohistochemical staining to allow 
calculation of the BrdU labelling index (LI). The staining procedure was based on a 
modified protocol of Sigma Inc (Table 5). After deparaffinization and rehydration, 
tissue sections were treated with prewarmed 0.1% trypsin solution at 37°C for 40 
minutes, followed by denaturation of the DNA with 2N HCl at 37°C for 30 minutes. 
In the next step sections were incubated with 1:50 monoclonal anti-BrdU antibody 
at 37°C for 1 hour, then blocked with avidin solution and subsequently with biotin 
solution for 5 minutes, respectively, followed by anti-mouse linked antibody for 1 
hour at room temperature, prior to the application of Neufuchsin solution for 20 
minutes. The sections were counterstained with hematoxylin, and coverslipped 
using ImmuMount (Shandon Inc).  
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Table 5. Protocol for BrdU immunohistochemical staining 
Reagents Company Order No. 
Trypsin tablets 
2N HCl 
TBS as was h-buffer 
Avidin-biotin blocking System 
Monoclonal anti-BrdU-Ab 
PowerVision 
DAKO Antibody Diluent 
0.2M Aminomethylpropandiol Buffer 
0.05M Tris buffer 
5% Neufuchsin solution 
4% Natriumnitrit solution 
Dimethylformamid solution 
NaCl 
Levamisole 
Naphtol-As-Bis-Phosphat 
Sigma, Germany 
Merck, Germany 
DAKO, USA 
DAKO, USA 
DAKO, USA 
Immuno Logic, Netherland 
DAKO, USA 
Merck, Germany 
Merck, Germany 
Chroma, Germany 
Sigma, Germany 
Merck, Germany 
Merck, Germany 
Sigma, Germany 
Sigma, Germany 
T-7168 
1.09063 
S1968 
X0590 
M0744 
DPVM-110 AP 
S0809 
801464 
8382 
1B467 
S-2252 
822275 
6404 
L-9756 
N-2250 
Equipments and Materials: 
wet chambers, staining jar, tissue drying oven, scale, 691 PH meter, Pipette (100ul, 1000ul), test 
tubes, ImmuMount 
Procedures:  
1. Deparaffinization and rehydration 
· Xylene 30 minutes 
· 100% methanol 3 minutes 
· 90% methanol 3 minutes 
· 70% methanol 3 minutes 
· Distilled water 3 minutes 
· Rinse in TBS for 5 minutes 
2. Enzymatic pre-treatment 
· Prepare trypsin-solution: dissolve 1 tablet in 1ml distilled water, prewarm it to 37°C 
· Apply 100µl of trypsin-solution on each slide, incubate it in the wet chamber at 37°C 
for 40 minutes 
· Rinse in TBS 
3. DNA denaturation 
· Put slides in pre-warmed (37°C) 2N HCl solution, incubate for 30 minutes at 37°C 
· Rinse thoroughly in TBS 
4. First antibody 
· Put the slides into the wet chamber,  
· Dilute BrdU-antibody with Antibody -Diluent 1:50 
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· Add 100ml/slide anti-BrdU antibody, incubate for 1 hour at 37°C 
· Rinse in TBS buffer for 3 minutes 
5. Blocking 
· Add 2 drops/slide of Avidin solution, incubate for 5 minutes 
· Rinse in TBS 
· Add 2 drops/slide of Biotin solution, incubate for 5 minutes 
· Rinse in TBS 
6. Link and label 
· Add 2 drops/slide of PowerVision (anti-mouse), incubate for 60 minutes at room 
temperature in the wet chamber 
· Rinse in TBS for 15 minutes 
7. Colour-reaction 
· Prepare the neufuchsin solution 
            Solution 1:  
o 18ml Aminomethylpropandiol buffer  
o 50ml 0.05M Tris buffer, pH 9.7 
o 0.6g NaCl 
o 28mg Levamisole 
                   Mix thoroughly 
            Solution 2:   
o 35mg Naphtol-As-Bis-Phosphat 
o 0.5ml Dimethylformamid 
            Mix thoroughly 
            Solution 3:   
o 8 drops 5% Neufuchsin-solution 
o 20 drops 4% Natriumnitrit-solution 
· Mix solution 1 with solution 3, then pour the mixture into solution 2 and mix them. Use 
2N HCl to adjust the pH-value to 8. 7 
· Filter the solution before using 
· Pour the solution into a staining jar, then put the slides into it 
· Incubate for 20 minutes at room temperature 
· Rinse with tap water 
8. Counterstaining 
· Put the slides in Haematoxylin, incubate for 30 seconds 
· Rinse in tap warm water to enhance the blue staining of the nuclei. 
· Apply coverslips with ImmuMount 
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2.6.2 Analysis of BrdU LI 
BrdU LI was determined by analysing 10 digital pictures which were taken at 200x 
magnification. A computer-assisted image analysis system was used (Table 6). 
After transferring the digital pictures to the computer, BrdU-labeled hepatocyte 
nuclei were counted using ImageTool 3.0, followed by the quantification of 
unlabeled hepatocyte nuclei using SigmaScan Pro 5.0 with an adapted macro. In 
this way, more than 3000 hepatocytes were counted per slide. The LI was 
calculated as the percentage of BrdU-labeled nuclei of hepatocytes out of counted 
hepatocytes (labeled + unlabeled hepatocytes). 
Labeling index (LI) = (number of BrdU-labeled nuclei in hepatocytes / number of 
counted hepatocytes) X 100% 
2.7 Validation of quantification method and immunohistochemical assay  
2.7.1 Comparison of methods to quantify unlabeled hepatocyte nuclei 
As the staining intensity varied within the same section and between different 
sections, the colour threshold must be adapted for each image to include 95% of 
the true hepatocyte nuclei.  
Three steps were accomplished to validate the quantification of unlabeled 
hepatocyte nuclei, including the comparison between conventional and computer-
assisted counting, followed by assessing the intra- and inter-observer 
reproducibility with computer-assisted counting.  
2.7.1.1 Correlation between conventional and computer-assisted counting 
1. Select 1 set of BrdU pictures randomly (Animal No. REG-032).  
2. Count the total numbers of unlabeled hepatocyte nuclei using ImageTool 
3.0 and Sigmascan Pro 5.0 respectively. 
3. Compare and analyse the differences statistically. 
2.7.1.2 Intra-observer reproducibility in computer-assisted counting 
1. Select 1 set of BrdU pictures randomly (REG-032). 
2. Count the total numbers of unlabeled hepatocyte nuclei using Sigmascan 
Pro 5.0 by 1 skilled observer on 2 different days (once per day). 
3. Compare and analyse the differences statistically. 
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Table 6. Protocol for analysis of BrdU LI 
Materials: 
· Digital camera (Nikon Coolpix 995, Tokyo 100-8331, Japan) 
· Compact Flash card (128MB, 206510, Japan) 
· Microscope (Olympus BX50) 
· Computer 
             Hardware: 
o CPU: AMD Athlon ™ 1.67GHz  
o RAM: 640MB 
o Hard disk: 110GB 
Software: 
o ImageTool 3.0 (developed in 2002 by the Department of Dental Diagnostic Science, The 
University of Texas Health Science Center, San Antonio, Texas, USA) 
o SigmaScan Pro 5.0 (developed in 1999 by SPSS Inc., Chicago, USA) with adapted macro 
Procedures:  
1. Digital pictures 
· Select 5 representative areas of portal tract and of central vein respectively, preferably 
away from major blood vessels. 
· Take 10 digital pictures totally with above areas at 200x magnification. 
· Transfer the pictures to the computer. 
· Organize the pictures of different animals into folders named with animal numbers.  
2. Quantification of BrdU-labeled hepatocyte nuclei  
· Import the digital pictures into ImageTool 3.0 one by one. 
· Identify and subsequently mark the BrdU-labeled nuclei of hepatocytes which are stained 
red. 
· Note the number given by ImageTool 3.0 automatically 
3. Quantification of unlabeled hepatocyte nuclei   
· Parametrize the unlabeled nuclei of hepatocytes based on 
o Colour* (blue) 
o shape (>0.6) 
o size (400-2500 pixels) 
· Use SigmaScan Pro 5.0 to count the number of the unlabeled nuclei of hepatocytes which 
are stained blue. 
· Record the number. 
4. Calculation of LI according to the above formula 
* Value for saturation was fixed while the hue value was adapted for each picture to include 95% of 
true hepatocyte nuclei.  
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2.7.1.3 Inter-observer reproducibility in computer-assisted counting 
1. Select 1 set of BrdU pictures randomly (REG-032). 
2. Count the total numbers of unlabeled hepatocyte nuclei using Sigmascan 
Pro 5.0 by 2 skilled independent observers. 
3. Compare and analyse the differences statistically. 
2.7.2 Assay precision of BrdU-IHC staining 
2.7.2.1 Quality criteria of BrdU-IHC staining 
The quality criteria for BrdU staining were standardized according to a scoring 
system, in which the intensity of positive signals in small bowel and liver tissue are 
the key points (Table 7). The sections which did not fulfil the criteria were excluded 
from further analysis and restained. 
 
Table 7. Quality criteria of BrdU-IHC staining 
Intensity of positive signals 
small 
bowel liver 
Consequence Explanation 
+~++ 
++ 
++ 
+~++ 
+ 
Accept it Acceptable staining quality 
+~++ 
++ 
(-)  
(including hepatocytes, 
bile duct cells and 
other non-parenchymal 
cells) 
Repeat it.  
If the intensity of 
positive signals are 
same, then accept it 
The possibility that liver tissue 
did not receive staining solution 
is unlikely to happen twice to the 
same slide 
(+) 
+ 
(-) 
(including hepatocytes, 
bile duct cells and 
other non-parenchymal 
cells) 
Repeat it.  
If the intensity of 
positive signals are 
same, then exclude it 
Potential staining or BrdU 
incorporation problems 
(+) 
Single hepatocytes 
clearly positive 
Repeat it.  
If the intensity of 
positive signals are 
same, then accept it 
Incorporation problem happens 
in small bowel but not in liver 
tissue 
++: strong positivity; +~++: moderate positivity; +: poor positivity; 
(+): very poor positivity; (-): negativity. 
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2.7.2.2 Intra-assay variation of BrdU-IHC staining 
To assess the intra-assay variation, a frequently used control sample, BLI-021, 
was stained in the same assay. The procedures were as follows: 
1. Cut 5 sections from the same paraffin block (BLI-021) as experimental 
slides.  
2. Perform BrdU-IHC staining in the same assay. 
3. Analyse the BrdU LI of each slide using computer-assisted counting 
respectively. 
4. Evaluate the intra-assay precision by calculating the coefficient of variance 
(CV). 
2.7.2.3 Inter-assay variation of BrdU-IHC staining 
To assess the inter-assay variation, BLI-021 was stained in different assays. The 
procedures were as follows: 
1. Cut 5 sections from the same paraffin block (BLI-021) as control slides.  
2. Perform BrdU-IHC staining in different assays. 
3. Analyse the BrdU LI of each slide using computer-assisted counting 
respectively. 
4. Evaluate the inter-assay precision by calculating the CV. 
 
2.8 Statistical analysis 
The data were analyzed with SPSS 11.0. Differences between 2 paired groups 
and between 2 independent groups were analyzed using paired- and independent-
samples Student’s t test, respectively. Multiple groups were compared using 
ANOVA followed by S-N-K analysis. Correlation between 2 data sets was 
evaluated using bivariate correlations analysis. P < 0.05 was considered 
significant. 
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3 RESULTS 
3.1 Validation of quantification method and immunohistochemical assay  
3.1.1 Comparison of methods to quantify unlabeled hepatocyte nuclei  
The total numbers of unlabeled hepatocyte nuclei generated automatically by 
computer-assisted counting were compared with those derived manually by 
ImageTool 3.0. The time required to quantify the number of unlabeled hepatocyte 
nuclei in one picture automatically was considerably less than that required to 
perform the counting manually (1-2 minutes vs. 8-10 minutes). Furthermore, no 
statistically significant difference was found between the two data sets using 
paired-samples t test (p=0.269) and a strong correlation between them was 
observed (r=0.868, p=0.001). (Table 8 and Figure 5)  
 
Table 8. Comparison between numbers obtained conventionally and automatically. 
Number of unlabeled hepatocyte nuclei Animal No. Picture No. 
ImageTool 3.0 Sigmascan Pro 5.0 
Differences 
CV032-1257 349 343 (135,190)* 6 
CV032-1258 327 310 (115,190) 17 
CV032-1259 355 367 (110,190) -12 
CV032-1260 341 334 (105,190) 7 
CV032-1261 369 366 (115,190) 3 
PT032-1247 357 339 (115,190) 18 
PT032-1253 354 350 (135,190) 4 
PT032-1254 322 329 (135,190) -7 
PT032-1255 335 343 (125,190) -8 
PT032-1256 315 305 (135,190) 10 
Sum  3424 3386 38 
REG-032 
Statistical analysis   P=0.269 
* In computer-assisted counting, the numbers together with their corresponding hue values of color 
threshold set by the observer were given.  
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Figure 5. Correlation between the numbers obtained conventionally and 
automatically. 
 
With computer-assisted counting, the total numbers of unlabeled hepatocyte nuclei 
counted by one skilled observer on two different days did not show any statistically 
significant difference using paired-samples t test (p=0.954) (Table 9). Similarly, to 
the same set of BrdU pictures, there was no significant difference between the 
numbers determined by two independent skilled observers using paired-samples t 
test (p=0.711) (Table 10). 
 
Table 9. Intra-observer reproducibility with computer-assisted counting 
Number of unlabeled hepatocyte nuclei Animal No. Picture No. 
Sigmascan-01  Sigmascan-02 
Differences 
CV032-1257 343 (135,190) 343 (135,190)* 0 
CV032-1258 310 (115,190) 319 (110,190) -9 
CV032-1259 367 (110,190) 367 (110,190) 0 
CV032-1260 334 (105,190) 334 (105,190) 0 
CV032-1261 366 (115,190) 353 (120,190) 13 
PT032-1247 339 (115,190) 339 (115,190) 0 
PT032-1253 350 (135,190) 350 (135,190) 0 
PT032-1254 329 (135,190) 329 (135,190) 0 
PT032-1255 343 (125,190) 346 (120,190) -3 
PT032-1256 305 (135,190) 305 (135,190) 0 
Sum  3386 3385 1 
REG-032 
Statistical analysis   P=0.954 
* In computer-assisted counting, the numbers together with their corresponding hue values of color 
threshold set by the observer were given.  
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Table 10. Inter-observer reproducibility with computer-assisted counting 
Number of unlabeled hepatocyte nuclei Animal No. Picture No. 
Observer-01  Observer-02 
Differences 
CV032-1257 343 (135,190) 342 (125,225)* 1 
CV032-1258 310 (115,190) 312 (120,235) -2 
CV032-1259 367 (110,190) 360 (120,225) 7 
CV032-1260 334 (105,190) 306 (130,240) 28 
CV032-1261 366 (115,190) 372 (120,235) -6 
PT032-1247 339 (115,190) 359 (120,225) -20 
PT032-1253 350 (135,190) 371 (130,215) -21 
PT032-1254 329 (135,190) 335 (130,223) -6 
PT032-1255 343 (125,190) 327 (130,220) 16 
PT032-1256 305 (135,190) 321 (130,225) -16 
Sum  3386 3405 -19 
REG-032 
Statistical analysis   P=0.711 
* In computer-assisted counting, the numbers together with their corresponding hue values of color 
threshold set by the observer were given.  
 
3.1.2 Assay precision of BrdU-IHC staining 
The intra- and inter-assay LI were in the range of 3.2-3.7% and 2.7 -3.5% 
respectively, from which the corresponding CV were obtained. Compared to the 
inter-assay CV, the intra-assay CV is lower (7.6% vs. 9.7%). There were no 
significant differences among the intra-assay LI as well as inter-assay LI using one 
way ANOVA test (p=0.962 and p=0.889 respectively)  (Table 11 and 12). 
 
Table 11. Intra-assay variation of BrdU-IHC staining 
Animal 
No. 
Assay 
No. 
Slide No. Intensity of 
small bowel 
LI (%) Mean SD CV 
(%) 
Statistical 
analysis 
W03-1485-1  +-++ 3.7 
W03-1485-2  +-++ 3.7 
W03-1485-3  +-++ 3.4 
W03-1485-4  +-++ 3.2 
BLI-021 BrdU-075 
W03-1485-5  +-++ 3.2 
3.4 0.3 7.6 
ANOVA: 
p=0.962 
 
 
Table 12. Inter-assay variation of BrdU-IHC staining  
Animal 
No. 
Slide No. Assay No. Intensity of 
small bowel 
LI (%) Mean SD CV 
(%) 
Statistical 
analysis 
BrdU-063  +-++ 2.9 
BrdU-065  +-++ 3.1 
BrdU-067  ++ 3.1 
BrdU-068  ++ 3.5 
BLI-021 W03-1485 
BrdU-070  ++ 2.7 
3.1 0.3 9.7 
ANOVA: 
p=0.889 
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3.2 Kinetics of regeneration after small-for-size liver transplantation 
The proliferation rate of normal rat liver was 0.2%. After 70%PH, a peak LI of 13% 
was reached at 24 hours, then the proliferation rate decreased gradually, returning 
to the preoperative value at 1 week (Figure 6). Compared to 70%PH, the onset of 
regeneration following 30%NAPOLT was delayed until 24 hours (13.1±8.4% vs. 
0.5±0.8%, p < 0.05) and peaked at 48 hours (5.6±4.3% vs. 15.8±9.3%, p < 0.05). 
There were no significant differences between 70%PH and 30%NAPOLT at 72 
hours and 1 week. In addition, the difference between the peak LI of 70%PH and 
30%NAPOLT group had no statistical significance (Table 13).  The corresponding 
BrdU pictures are shown in Figure 7 and 8.  
 
Table 13. Kinetics of liver regeneration following 70%PH and 30%NAPOLT (data 
are expressed as mean ± SD %). 
Observation Periods 
Group 
0h 24h 48h 72h 1w 
Naive 
0.2±0.1% 
(n=10) 
    
70%PH  
13.0±8.4% 
(n=6) 
5.6±4.3% 
(n=6) 
4.4±1.6% 
(n=6) 
0.3±0.2% 
(n=4) 
30%NAPOLT  
0.5±0.8%* 
(n=5) 
15.8±9.3%* 
(n=4) 
4.2±1.7% 
(n=5) 
2.1±2.3% 
(n=4) 
Compared to 70%PH group, * p<0.05. 
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Figure 6. Kinetics of regeneration following 70%PH and 30%NAPOLT. The BrdU 
LI showed a peak value of 13% at 24 hours after 70%PH, which declined gradually 
thereafter. The onset of liver regeneration was delayed after 30%NAPOLT, 
starting at 24 hours and reaching a peak value at 48 hours. Its magnitude was 
similar to that at 24 hours after 70%PH. The regeneration rates in both groups 
decreased to the same values at 72 hours postoperatively. (Compared to 70%PH 
group, * p<0.05) 
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70%PH-24h (REG-038-DSCN6688) 70%PH-48h (REG-144-DSCN0351) 
70%PH-72h (REG-155-DSCN0648) 70%PH-1w (REG-199-DSCN0139) 
Figure 7. BrdU LI at different time points after 70%PH (control group): 24h (upper 
left), 48h (upper right), 72h (lower left) and 1 week (lower right). 
BrdU LI peaked at 24 hours and decreased gradually thereafter. Proliferating 
hepatocytes were uniformly distributed in the lobules at 24h. At 48h and 72h, not 
only hepatocytes but also biliary epithelial cells, Kupffer cells as well as sinusoidal 
endothelial cells underwent proliferation. (BrdU, 200x).  
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30%NAPOLT-24h (PA-68_BrdU_Z2) 30%NAPOLT-48h (PA-67_BrdU_P1) 
30%NAPOLT-72h (PA-70_BrdU_Z1) 30%NAPOLT-1w (PA-136_BrdU_P1) 
Figure 8. BrdU LI at different time points after 30%NAPOLT: 24h (upper left), 48h 
(upper right), 72h (lower left) and 1 week (lower right). 
The onset of proliferation following 30%NAPOLT started at 24h and peaked at 48h 
postoperatively, decreasing gradually thereafter. Proliferating cells were uniformly 
distributed in the lobules at 48h, majority of them being hepatocytes. At 72h 
proliferating Kupffer cells were detected. (BrdU, 200x).  
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3.3 Influence of extended cold ischemia on regeneration of a small-for-
size graft 
Transplantation of a 30% partial liver graft subjected to1 hour of cold ischemia was 
tolerated by all animals. Extending cold ischemia to both 3 and 5 hours reduced 
the 1-week survival rate to 50% and 30%, respectively (Table 14). The BrdU LI 
tested at 48 hours after 70%PH showed 5.6%. The proliferative rate of a 30% liver 
graft subjected to 1-hour cold ischemia was significantly higher at the same time 
point (p<0.05), as onset and peak of proliferation were delayed. The influence of 
prolonged ischemia on proliferation rates was assessed at 48h postoperatively 
(n=3-4/group) and was associated with a lower mean LI, although the difference 
did not reach statistical significance (Table 14 and Figure 9). The corresponding 
BrdU pictures are shown in Figure 10. 
 
Table 14. Effects of cold ischemia on the survival rate and regenerative ability of 
the liver (data are expressed as percentage and mean ± SD %, respectively). 
Group Ischemic time 1 week SVR  BrdU LI at 48h 
70%PH control 100% (6/ 6)  5.6±4.3% 
Ischemia 1h 100% (6/ 6)  15.8±9.3%* 
Ischemia 3h  50% (5/10)  9.1±1.3% 30%NAPOLT 
Ischemia 5h  30% (3/10)  9.3±7.8% 
*: Compared to the control group, p<0.05. 
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Figure 9. Effect of cold ischemia on the regenerative capacity of a 30% partial 
liver graft (compared to the control group, *p<0.05). 
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70%PH-Control (REG-144-
DSCN0351) 
30%NAPOLT-Ischemia 1h (PA-
067_BrdU_P1) 
30%NAPOLT-Ischemia 3h (PI-
067_BrdU_P1) 
30%NAPOLT-Ischemia 5h (PI-
071_BrdU_P1) 
Figure 10. Influence of cold ischemia on BrdU LI (48 hours postoperatively).  
Control group: 70% PH (upper left), experimental groups: 30%NAPOLT  
subjected to 1h cold ischemia (upper right), to 3h (lower left) and to 5h 
(lower right). Labeling indices were reduced in animals subjected to  
Prolonged ischemia. (BrdU 200x) 
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3.4 Immunological regulation of liver regeneration 
3.4.1 Immune activation by vaccination on liver regeneration 
After 70%PH, both the control and the vaccinated group reached their 
regeneration peaks at 24h. However, compared to the control group, the peak 
value of the vaccinated group was significantly lower (13.0±8.4% vs. 4.4±4.1%, 
p<0.05). Moreover, the LI at 48h and 72h postoperatively of the vaccinated group 
was significantly lower than those of the control group (5.6±4.3% vs. 1.6±1.0%, 
p<0.05, and 4.4±1.6% vs. 1.2±0.7%, p<0.01, respectively). Thereafter the 
proliferation rates of both groups decreased gradually, returning to baseline at 1 
week postoperatively (Table 15 and Figure 11). The corresponding BrdU pictures 
are shown in Figure 12. 
 
Table 15. Regeneration kinetics of control and vaccinated group following 70%PH 
(data are expressed as mean ± SD %). 
Observation Periods 
Group 
0h 24h 48h 72h 1w 
Naive 
0.2±0.1% 
(n=10) 
    
Control  
13.0±8.4%* 
(n=6) 
5.6±4.3%* 
(n=6) 
4.4±1.6%** 
(n=6) 
0.3±0.2% 
(n=4) 
Vaccinated  
4.4±4.1% 
(n=6) 
1.6±1.0% 
(n=6) 
1.2±0.7% 
(n=6) 
0.4±0.2% 
(n=6) 
Compared to vaccinated group: * p<0.05. ** p<0.01 
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Figure 11. Kinetics of regeneration in control and vaccinated group following 
70%PH. Although the kinetics of regeneration in the experimental group was 
similar to the control group, the LI at 24h, 48h as well as 72h were significantly 
lower. (Compared to vaccinated group: * p<0.05; ** p<0.01) 
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 70%PH-24h (REG-029-DSCN8509)  70%PH-48h (REG-192-DSCN0049) 
 70%PH-72h (REG-204-DSCN0330)  70%PH-1w (REG-210-DSCN0287) 
Figure 12. BrdU LI at different time points after 70%PH in animals subjected to 
hepatitis B vaccination 1 week before. 24h (upper left), 48h (upper right), 72h 
(lower left) and 1 week (lower right). 
Compared to the control group, proliferation reached a lower peak at 24 hours 
and decreased gradually thereafter. At 48h and 72h, majority of the proliferating 
cells were biliary epithelial cells, Kupffer cells and sinusoidal endothelial cells. 
( BrdU, 200x).  
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3.4.2 ffect of inhibiting immune activation by immunosuppressive drugs on 
liver regeneration 
Subtotal reduction of the liver mass was followed by a survival rate of 50% in the 
control group. Treatment with calcineurin inhibitors increased the short-term 
survival in both groups. 75% of the animals treated with CsA and 63% of those 
treated with FK506 survived up to 48 hours postoperatively. Treatment with RAD 
did not show any effects on the survival rate when compared with the control 
group, whereas MMF reduced the survival rate dramatically to 21%, which was the 
reason to increase the group size (Table 16).   
Treatment with CsA augmented liver regeneration as indicated by the increased 
BrdU LI compared to the control group (p<0.05). Animals receiving FK506 
presented with a regenerative rate of 15.5%, which was similar to that of the 
control group. However, animals treated with either MMF or RAD showed a much 
lower regenerative rate (p<0.05 and p<0.01, respectively) (Figure 13). The 
corresponding BrdU pictures are shown in Figure 14. 
 
Table 16. Effects of different immunosuppressive drugs on the survival and 
regeneration rate of the liver after 90%PH (data are expressed as percentage and 
mean ± SD %, respectively). 
PH Treatment 48 hours SVR BrdU LI 
Control 50% (4/8) 12.2±2.3% 
CsA 75% (6/8) 18.5±7.5%* 
FK506 63% (5/8) 15.5±7.6% 
MMF 21% (3/14) 4.3±4.3%* 
90%PH 
RAD 50% (4/8) 1.1±1.2%** 
Compared to the control group, *p<0.05, **p<0.01. 
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Figure 13.  Effects of different immunosuppressive drugs on the regeneration rate 
of the liver at 48 hours after 90%PH (Compared to the control group, *p<0.05, 
**p<0.01). 
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 90%PH-CsA (RIL-018_BrdU_Z2) 90%PH-FK (RIL-043_BrdU_P2) 
   90%PH-MMF (RIL-053_BrdU_P2)   90%PH-RAD (RIL-010_BrdU_Z1) 
 90%PH-Control (RIL -026_BrdU_P1) 
Figure 14. BrdU LI in rats subjected to 90%PH and treated with different 
immunosuppressive drugs (48h postoperatively). Treatment with CsA 
(upper left), with FK506 (upper right), control animal receiving no treatment 
(middle), with MMF (lower left), and with RAD (lower right). 
Labeling index was increased in animals subjected to CsA treatment and 
almost abrogated in animals receiving MMF and RAD (BrdU, 200x) 
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4 DISCUSSION 
4.1 Validation of quantification method and immunohistochemical assay  
4.1.1 Correlation between conventional and computer-assisted counting 
The interest in cell proliferation in response to partial hepatectomy or toxic injury 
has led to a rapidly growing demand for assessment of cell turnover. A widely 
used technique in animal models is to administer a halogenated pyrimidine, BrdU, 
and to visualize its incorporation into the DNA during the S phase by 
immunohistochemistry (Magavi and Macklis, 2002). Labelled and unlabeled 
hepatocyte nuclei are then counted by an observer and the percentage of cells 
that incorporated the nucleotide during S phase are calculated. 
Some progress has been made in automating this process. Soames indicated that 
automated image analysis can reduce inter-observer variation and should 
minimize intra-observer error, as well as reducing the tedium of measuring the 
labelling indices in the liver (Soames et al., 1994b). A macro with object-targeted 
adaptation of SigmaScan Pro 5.0 was developed previously in our group which 
enabled us to automate the counting of unlabeled hepatocyte nuclei and generate 
LI subsequently. The time required to perform the computer-assisted counting is 
much less than that required performing the counting conventionally using 
ImageTool 3.0.  
Since the pioneering report by Soames et al. (Soames et al., 1994a) on 
quantifying hepatocyte nuclei by image analysis, no other reports characterized a 
similar work. Using a monochrome camera, which provides a gray scale image 
only, they developed an algorithm based on nuclear size and shape to distinguish 
hepatocyte nuclei from other cell types leading to an inclusion of 90% true 
hepatocytes (Table 17). We used a consumer camera to acquire colour images for 
data documentation and analysis. Therefore our parametrization included colour 
threshold besides nuclear size and shape. In order to compensate for slight 
differences in staining intensity between different slides, the hue values for the 
colour threshold were adapted for each image prior to quantification until 95% of 
the hepatocyte nuclei were included.  
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In both studies, a strong correlation was shown between conventional and 
computer-assisted counting. Furthermore, in the current study, no statistically 
significant differences were found in either intra- or inter-observer data sets, 
indicating that a reproducible and reliable result was achieved using computer-
assisted counting.  
 
Table 17. Computer-assisted quantification of hepatocyte nuclei in rodents 
Author Object 
Camera/ 
Program 
Parameter Quality control 
Statistical 
results 
Sony XC-7CE 
monochome CCD Soames 
1994 
Total 
hepatocytes 
nuclei in rat 
and mouse 
liver (>90%) 
Kantron Vidas 2.1 
Nuclear size 
(>25 um2) 
Shape (>0.7) 
Correlation between 
conventional and 
computer-assisted 
counting 
Strong 
correlation 
Nikon Coolpix 995 
Correlation between 
conventional and 
computer-assisted 
counting 
Strong 
correlation 
Current 
study 
Unlabeled 
hepatocytes 
nuclei in rat 
liver (>95%) 
SigmaScan Pro 
5.0 with adapted 
macro 
Nuclear size 
(400-2500 
pixels) 
Shape (>0.6) 
Colour (blue) 
Intra- and inter-
observer 
reproducibility 
No 
significant 
difference 
 
4.1.2 Assay precision of BrdU-IHC staining 
In recent years, IHC has become an indispensable technique in modern scientific 
research. However, the technique is very sensitive to a variety of factors such as 
tissue fixation and processing, antigen retrieval, choice of antibodies and detection 
systems (Ruiter et al., 1998). In order to achieve comparable results between 
different laboratories, but also within the same laboratory, these factors have to be 
standardized. Furthermore, differences in results can also be related to the 
evaluation method. To achieve consistent results, a standard staining protocol was 
used and only slides fulfilling the quality criteria were included in the analysis 
(Table 7). 
The interpretation of immunohistochemical staining is based on the use of 
appropriate positive and negative internal and/or external controls. O'Leary 
indicated that the control specimen should not exhibit intense immunoreactivity for 
 
42 
the antigen in question, but should ideally demonstrate immunoreactivity that is 
weak in some places and strong in others. This is most readily accomplished 
through the use of multi-tissue blocks (O'Leary, 2001). Accordingly all 
experimental samples were embedded in multi-tissue blocks containing liver, small 
bowel as well as kidney tissue as internal control.  The intensity of positive signals 
in small bowel and liver tissue were the key points of the quality criteria (Table 7). 
In addition, an animal with a moderate regeneration rate following hepatectomy 
(BLI-021) was used as control sample.  
To assess the assay precision of BrdU-IHC staining, the control sample was 
stained and evaluated repeatedly to test the intra- and inter-assay variations. The 
intra- and inter-assay CV were 7.6% and 9.7%, respectively. Being unaware of 
any published data characterizing the assay precision of BrdU-IHC staining, we 
evaluated these results in two aspects. On one hand, intra- and inter-assay CV 
below 10% in enzyme-linked immunosorbent assay (ELISA) is usually considered 
acceptable and reproducible (Austin et al., 2001). Since IHC shares the basic 
principle with ELISA using enzymatic colour reaction to detect the binding of 
antigen and antibody, this criteria might be adapted to the evaluation of assay 
precision of BrdU-IHC staining. In this aspect, the results suggested an acceptable 
intra- and inter-assay variability. On the other hand, statistical methods can be 
used to judge the significance of the assay variability. Using one way ANOVA test, 
there were no significant differences among the intra-assay LI as well as inter-
assay LI (p=0,962 and p=0,889 respectively). Therefore, we concluded that our 
BrdU-IHC staining was reproducible, reliable and of high precision. 
4.2 Kinetics of regeneration after small-for-size liver regeneration 
4.2.1 Delayed onset of regeneration after transplantation  
Loss of liver mass is being compensated by liver regeneration which starts in any 
case after a reduction of functional liver mass by any means, irrespectively of the 
etiology (Andiran et al., 2000). The final size of the liver is determined by the 
needs of the host, as the liver is growing to adjust its size according to the 
requirement of the host (Francavilla et al., 1994b). As transplantation of a small-
for-size graft is unavoidable in living liver donation between adults, recovery of 
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functional liver mass by hepatocyte proliferation is one of the crucial factors for the 
success of the procedure.  
According to the experience obtained from the standard resection model and 
confirmed in this experiment, liver regeneration starts within hours after resection, 
and the maximal proliferation index is observed between 18 and 30 hours (Assy et 
al., 1998). In this study, the BrdU LI at 24 hours after 70%PH showed a maximal 
value of 13%, which declined gradually thereafter. The  maximal LI, which was 
observed after transplanting a graft of similar size (30%) as the remnant liver after 
70% resection, reached the same magnitude. However, initiation of regeneration 
was delayed. The peak was reached 24 hours later on postoperative day (POD) 2 
than in the resection model. This observation suggested that the small-for-size 
liver graft is capable of regeneration similarly to a remnant liver of the same size, 
but follows a different kinetics.  
Few other reports addressed this question (Table 18). In addition, comparison of 
results is difficult as the experimental design varies considerably in respect to 
species, graft size, number and time point of observation during the course of 
regeneration. Furthermore, although determination of regeneration rate is based 
on the BrdU LI, the assay and its evaluation varies in respect to the primary 
antibody as well the detection system and the quantification method. Results were 
expressed as hepatocytes/HPF and in percentage of proliferating hepatocytes. 
The group of Kikuchi and Yamaguchi  (Kikuchi et al., 1994; Yamaguchi et al., 1996)  
performed a detailed kinetic study with observation points every 12 h post 
operation. They used the same graft volume, a similar transplantation technique 
(perfusion of liver graft with heparinized saline solution, non-arterialized 
transplantation) but a different syngeneic model. In contrast to our reported results, 
initiation of regeneration was not delayed. However, the peak proliferation rate 
was also postponed. They observed 15% proliferating hepatocytes in the 
periportal areas at 24h followed by the maximal proliferation rate of 25% at 36h, 
which was 12 hours later than after 70%PH.  
The other authors reported a peak proliferation rate at 48 hours or in case as late 
as 72 hours, but did not obtain the time course of liver regeneration, as they only 
measured the proliferation rate on day 2 and day 4 or on day 1 and 3 after 
transplantation (Conzelmann et al., 2003; Selzner et al., 2002a; Uchiyama et al., 
1999).  
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Table 18. Kinetics of liver regeneration following syngeneic POLT with various 
graft volumes in two rodent models  (using BrdU LI as proliferation parameter) 
Regeneration rate  Author and 
publish year 
Graft 
volume 
Rat 
strain d11 d2 d3 d4 
Tanaka et al., 
2003 
20% DA-DA 30% 28% 27% Not done 
Periportal areas 
15% 5% 5% Not done 
Pericentral areas 
Kikuchi et al., 
1994 
Yamaguchi et 
al., 1996 
30% Wistar-Wistar 
5% 8% 5% Not done 
Selzner et al., 
2002 
30% Lewis-Lewis Not done 
43 
(pos2 HC3 
/ HPF4) 
Not done 
38% 
(pos HC/ 
HPF) 
Conzelmann 
et al., 2003 
50% 
Male C57B1/6 
mice 
Not done 32% Not done Not done 
Uchiyama et 
al., 1999 
60% Lewis-Lewis 0.7% Not done 1.6% Not done 
Own study 30% Lewis-Lewis 0.5% 15.8% 4.2% Not done 
d1 : day; d  pos2 : positive;  HC3 : hepatocytes;  HPF4: high power fields (200x). 
 
4.2.2 Possible explanations for the delayed onset of regeneration 
There are several possible explanations for the delay in initiation of regeneration in 
animals undergoing partial liver transplantation. First of all, the small functional 
liver volume subsequent to extended resection and/or impaired by the additional 
ischemia-reperfusion injury during the transplantation procedure may limit liver 
regeneration, as the liver must be capable of maintaining its normal metabolic 
functions at the same time as undergoing cell division (; Broering et al.  2003).  
Furthermore, initiation of liver regeneration requires the presence of a variety of 
growth factors, which are released locally during liver resection. As in this 
experiment the liver was flushed during the transplantation procedure with 10ml of 
saline solution, these growth factors might have been washed out leading to the 
delayed onset of regeneration as suggested by Bolitho (Bolitho et al., 1995). 
However, the importance of flushing the liver in respect to the onset of 
regeneration remains questionable, as Kikuchi and Yamaguchi did not observe 
delayed initiation in their experiments. 
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In conclusion, the small-for-size liver graft is capable of regeneration similar to the 
situation following PH, with a slightly postponed time course. 
 
4.3 Influence of extended cold ischemia on regeneration of a small-for-
size graft 
Although LDLT is associated with shorter periods of cold ischemia compared to 
cadaveric transplantation, ischemia-reperfusion injury cannot be completely 
avoided. As the recipient only receives a partial graft, which has to regenerate in 
order to compensate for the size reduction, it is of importance to assess the impact 
of the duration of cold ischemia on regeneration.  
4.3.1 Extended ischemia reducing liver regeneration 
This question was addressed using the 30% partial liver transplantation model and 
subjecting the graft to different periods of cold ischemia. In order to compare the 
results to the previous kinetic study, where grafts were subjected to 1-hour cold 
ischemia without the use of a preservation solution, a prolonged cold ischemia 
time of 3- and 5-hour was selected. The 1-week survival rate was reduced to 50% 
and 30% respectively after 30%NAPOLT, when grafts were subjected to 3- and 5-
hour cold ischemia.  Analysis of LI at POD 2 showed a reduced rate of proliferating 
hepatocytes after extended cold ischemia although not reaching statistical 
significance. This result is supported by the observations of Selzner (Selzner et al., 
2002c), who is up to now the only other author investigating this problem. He used 
the same model of rat partial liver transplantation (30%NAPOLT in Lew-Lew), but 
he subjected the graft to considerably longer cold ischemic time. In contrast to the 
present study, where grafts were flushed with saline, he used University of 
Wisconsin (UW) as organ preservation solution to reduce ischemia-reperfusion 
injury (Table 19). 
Although Selzner’s experimental setup was different from ours, the key 
observation, that prolonged ischemia reduced the hepatocyte proliferation rate on 
POD 2, was similar. In his experiment, proliferation was reduced to one fourth 
compared to the control group, whereas our results showed a reduction albeit not 
reach statistical significance. This may be due to several reasons.  First of all, he 
subjected the graft to 10-16 hours of cold ischemia, whereas we used only 3-5 
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hours. This prolonged ischemia time might have had a more pronounced effect, 
although he applied UW solution for organ preservation. Furthermore, as we 
mentioned before, the route and dosage of BrdU administration as well as the 
evaluation method between the two studies were different (Table 19). He used a 
dose twice as high, as well as an in-vivo incubation time in the animal, which was 
twice as long. Instead of calculating an index based on a reasonable total number 
of hepatocytes (we counted at least 3000 HC/rat), he only quantified the number of 
positive hepatocytes per high power field (200x). Depending on the selection of 
the high power field (size of portal field or central vein or confluent necrosis) the 
result may be inaccurate.  
 
Table 19. Influence of duration of cold ischemia on regeneration 
Author Model 
Ischemic 
time 
Preservation 
solution 
BrdU 
LI (d2) 
BrdU 
dose  
Route of 
injection 
Evaluation 
method 
Selzner 
2002 
Lew-Lew 
30%NAPOLT 
30 min1 
10h2 
16h 
UW 
43 
10 
5 
100m
g/kg 
Ip4. 2h 
before 
sacrifice. 
No. of labelled 
HC / HPF 
own 
study 
Lew-Lew 
30%NAPOLT 
1h 
3h 
5h 
saline 
15% 
9% 
9% 
50mg
/kg 
Iv3. 1h 
before 
sacrifice. 
(No. of 
labelled HC5) / 
(total HC in 10 
HPF6) x 100% 
min1 : minutes;   h2  : hour(s);   iv3  : intravenously;  ip4 : intraperitoneally;   
HC5  : hepatocytes;  HPF6  : high power fields (200x). 
 
4.3.2 Speculation regarding the mechanism  
Tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6) are major and 
initial growth factors involved in regeneration in vivo (Cressman et al., 1996; 
Fausto et al., 1995; Yamada et al., 1997). Selzner postulated that short period of 
cold ischemia may stimulate nonparenchymal cells, possibly sinusoidal endothelial 
and Kupffer cells, through yet unknown mechanisms, to produce growth factors 
such as TNF-alpha and IL -6 (Selzner et al., 2002d). This could be one of the 
mechanisms explaining the slightly elevated proliferation rate after full-size liver 
transplantation, where the recipient did not experience a major loss of functional 
liver mass (Takata et al., 1993).  
It was reported repeatedly that prolonged cold ischemia followed by reperfusion of 
the liver graft impaired Kupffer cell function and increased apoptotic cell death of 
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sinusoidal endothelial cells (Caldwell-Kenkel et al., 1989; Clavien, 1998; Gao et al., 
1998; Thurman et al., 1988).  Injury of nonparenchymal cells during reperfusion 
may result in decreased production of the acute reactant cytokines TNF-alpha and 
IL-6, thereby preventing adequate hepatocyte proliferation. Kupffer cell blockade 
also caused impaired regeneration, possibly through decreased availability of 
TNF-alpha and IL-6 (Meijer et al., 2000; Selzner et al., 2003).  
As cold ischemia is impairing liver regeneration, special efforts should be 
undertaken to keep the already short ischemic time in living donation even shorter, 
especially when the graft-to-liver weight ratio is low.  
4.4 Immunological regulation of liver regeneration  
Recently we proposed a feedback mechanism regarding the immunological 
regulation of liver regeneration (; Dahmen and Dirsch 2002). It was hypothesized 
that liver regeneration and immune activation are inversely related, and inhibition 
of immune activation by administration of immunosuppressive drugs could 
enhance the regenerative response (Figure 15). 
 
Hypothesis: Liver regeneration and 
immune activation are related inversely 
• Regeneration is inducing a general immune 
activation
• Immune activation itself is inhibiting regeneration
=> Inhibition of immune activation is enhancing the 
regenerative response
Regeneration
Immune activation
Feed back mechanism
 
Figure 15.  The feedback mechanism between liver regeneration 
   and immune activation 
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4.4.1 Feedback mechanism between liver regeneration and immune 
activation 
4.4.1.1 Experimental evidence supporting the hypothesis 
It has been demonstrated that the liver has the function of a hematolymphoid 
organ closely associated with the systemic hematolymphoid system (Sakamoto et 
al., 1992). Several phenomena such as alteration of extrathymic T cells in the liver 
(Sato et al., 1993a), activation of natural killer cells (NK cells) and autoreactive T 
cells (Ono et al., 1984) as well as suppressor T cells against the allogeneic 
response (Pinto et al., 1987) were observed in animal experiments after PH. 
Therefore, it was hypothesized, that liver regeneration following hepatectomy is 
inducing systemic immunological activation.  
On the other hand, there is considerable evidence that immune activation 
associated factors on the cellular as well as the humoral level may inhibit liver 
regeneration. Three observations are described here. Ohnishi suggested that NK 
cells activated by IFN-gamma may be involved in killing the regenerating liver cells 
(Ohnishi et al., 1993). Tanaka reported that infusion of lymphokine activated killer 
(LAK) cells was followed by inhibition of liver regeneration after partial 
hepatectomy in mice (Tanaka et al., 1993a). Vujanovic studied the phenotype and 
function of NK cells residing in the liver after 70%PH, and suggested that these NK 
cells may be involved in the regulation of the extent of liver regeneration 
(Vujanovic et al., 1995). All the above experimental results suggested that immune 
activation inhibited liver regeneration inversely. 
4.4.1.2 Animal model and experimental design 
We wanted to confirm this hypothesis using Hepatitis B vaccination as stimulus for 
systemic immune activation prior to liver resection. As hepatitis B-related liver 
diseases represent a major indication for liver transplantation, it is of interest to 
assess the influence of a viral-related immune activation on the course of 
regeneration. In order to exclude other effects such as flushing of the remnant liver 
and/or additional ischemia-reperfusion injury during the transplantation procedures, 
the standard 70%PH model was chosen for this experiment. 
Hepatitis B vaccination leads to a similar albeit weaker stimulation of the immune 
system as in the host during the infection with the hepatitis B virus, when the 
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immune system tries to eliminate the virus (; Keating and Noble 2003) although 
the T-cell compartment is not involved to the same extent .  
ENGERIX-B (GlaxoSmithKlein Biologicals, Belgium) was selected for vaccinating 
the rats prior to liver resection, as it is a noninfectious recombinant DNA hepatitis 
B vaccine containing purified surface antigen (S protein). Following recognition by 
B cells, this antigen induces production of specific anti-HBs antibodies not only in 
humans, but also in the rat as demonstrated previously (Dahmen et al., 2002; 
Dahmen et al., 2003; Gu et al., 2002; Li et al., 2002).  
4.4.1.3 Possible mechanism of the inhibitory effort of immune activation on 
liver regeneration 
Indeed, we observed that liver regeneration was impaired in the vaccinated 
animals. The course of regeneration remained unaffected, but the peak of 
proliferation was significantly lower, suggesting an inhibitory effect of immune 
activation on the proliferating kinetics following 70%PH.  
Processing and presentation of the HBsAg via the major histocompatibility 
complex (MHC) class II pathway results in the priming of the CD4+ T cell response  
and provides efficient T cell ‘’help’’ for B lymphocytes to synthesize specific anti-
HBs antibodies (Schirmbeck et al., 1994; Wild et al., 1999). Th1 cells induce an 
immune response by secreting cytokines such as IFN-gamma and IL-2 
(Jafarzadeh and Shokri, 2003). Two recent studies revealed that vaccination with 
recombinant HBsAg induced the increased production of these two cytokines 
(Akbar et al., 1999; Vingerhoets et al., 1994).  
IFN-gamma is a glycoprotein produced mainly by T cells in response to specific 
sensitizing antigens. It was proven to be a substance which activates NK cells 
(Trinchieri, 1989). Sato reported that IFN-gamma inhibits liver regeneration by 
stimulating MHC II antigen expression in the regenerating liver (Sato et al., 1993b). 
They subsequently revealed IFN-gamma mRNA expressions decreased in the 
liver on day 1 after 70%PH but increased clearly thereafter (Sato et al., 1999). In 
addition, Lai observed that the elevation of serum IFN-gamma on day 5 after 
70%PH was three times higher than the preoperative data (Lai et al., 1996). These 
studies suggested that IFN-gamma may negatively regulate liver regeneration.  
IL-2 belongs to lymphohematopoietic cytokines and plays a critical role in the 
promotion and enhancement of cellular response. It is responsible for the 
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regulation of T lymphocytes proliferation and the activation of cytotoxic T 
lymphocytes (CTL), NK cells, macrophages as well as granulocytes (Lyszkiewicz 
and Pajtasz-Piasecka, 2002).  
Okamura (Okamura et al., 1992a) reported already in 1992, that liver regeneration 
was inhibited by treatment with IL-2. His observation was confirmed by Tanaka 
(Tanaka et al., 1993d) and later by others, who also reported that regeneration 
was suppressed following treatment with IL -2 (Liu et al., 2002; Wadamori et al., 
1996) (Table 20). 
 
Table 20. IL-2 treatment inhibits liver regeneration  
Author/ 
Publish year 
Model Treatment Effect on liver 
regeneration 
Mechanism  
Okamura et 
al., 1992 
70%PH IL-2, 
intramuscularly 
injection 
Liver regeneration 
was blocked by IL-2 
IL-2 participates in 
converting NK cells into 
activated killer cells 
Tanaka et al., 
1993 
70%PH IL-2,  
intraperitoneal 
injection 
BrdU LI at 36 hours 
was suppressed in a 
dose-dependent 
manner 
Not mentioned 
Wadamori et 
al., 1996 
70%PH IL-2, portal 
infusion 
Liver regeneration 
was suppressed 
IL-2 not impaired cell 
proliferation, but 
reappearance of gap 
junctions, which could be a 
kind of maturation of 
hepatocytes, was affected 
by IL-2 
Liu et al., 2002  66%PH IL-2 Liver regeneration 
was blocked by IL-2 
IL-2 enhanced NK activity 
 
In summary, vaccination induced immune activation impaired liver regeneration, 
possibly through the increased production of IFN-gamma and IL-2. 
 
4.4.2 Enhancement of the regenerative response by inhibition of immune 
activation 
4.4.2.1  Experimental evidence supporting the hypothesis 
Complementary to the studies describing the inhibitory effect of IL -2 administration 
on liver regeneration are the reports describing the hepatotrophic effects of the IL-
2–blocking calcineurin inhibitors.  
The first observation regarding the effect of CsA on liver regeneration was 
obtained in 1988  and attributed the hepatotrophic effect to an increased activity of 
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ODC and TK induced by CsA (Kahn et al., 1988). In the same year Kim postulated 
a direct trophic effect on hepatocytes (Kim et al., 1988a; Kim et al., 1988b), but 
also suggested that the inhibition of the T cell response was involved in the 
enhancement of regeneration. Since 1989 some evidence was given that the 
effect was related to the inhibition of IL-2 production (Francavilla et al., 1989b; 
Morii et al., 1999; Tanaka et al., 1993c). However, there is also evidence that the 
hepatotrophic effect is related to other mechanism such as mediated by increasing 
the cellular Ca++ pools (Provencher and Gascon-Barre, 2002) (Table 21).  
 
Table 21. Effect of CsA on liver regeneration 
Mechanism  Author/ Publish 
year 
Model  Effect on liver 
regeneration cytokine related Cell related 
Kahn et al., 1988 70%PH Hepatotrophic Not mentioned Not mentioned 
Kim et al., 1988 70%PH Hepatotrophic Not mentioned -Direct trophic effect on 
hepatocytes 
-Inhibition of T cell 
responses 
Francavilla et al., 
1989 
40%PH 
70%PH 
Hepatotrophic Inhibition of IL-2 
production and 
binding 
Inhibition of T cell 
response 
Kim et al., 1990 70%PH Hepatotrophic Not mentioned -Activation of hepatic 
metabolism 
-Inhibition of T cell 
responses 
Tanaka et al., 
1993 
70%PH Hepatotrophic Inhibition of IL-2 
production and 
binding 
Inhibition of NK cell 
responses 
Morii et al., 1999 70%PH Hepatotrophic 
 
-Inhibition of IL-2 
production 
-Decrease of TGF-ß 
production in liver 
tissue  
-Inhibition of TNF-a 
expression 
-Inhibition of T cell, with 
minimal influence against 
B cell functions 
 
Provencher and 
Gascon-Barre, 
2002 
70%PH Accelerate 
hepatic 
compensatory 
growth 
Not mentioned In part by increasing the 
cellular Ca++ pools 
 
 
As FK506 influences the IL -2 production negatively similarly to CsA, comparable 
results were obtained when evaluating the effect on liver regeneration. 
Enhancement of liver regeneration was demonstrated repeatedly and was also 
attributed to the inhibition of IL-2 production (Bendahan et al., 1994; Francavilla et 
al., 1989a; Francavilla et al., 1990; Okamura et al., 1992b; Sato et al., 1992; 
Tanaka et al., 1993b). Other mechanism was also suggested such a regeneration 
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promoting effect mediated by up-regulating of the insulin receptors in the 
regenerating rat liver (Escribano et al., 2002) (Table 22). 
 
Table 22. Effect of FK506 on liver regeneration 
Mechanism  Author/ 
Publish year 
Model  Effect on liver 
regeneration cytokine related Cell related 
Francavilla et 
al., 1989 
40%PH 
70%PH 
Hepatotrophic Inhibition of IL-2 
production and binding 
Inhibition of T cell 
response 
Francavilla et 
al., 1990 
70%PH Hepatotrophic Inhibition of IL-2 
production 
Inhibition of the T 
cell component  
Sato et al., 
1992 
70%PH Hepatotrophic Inhibition of IL-2 
production 
Not mentioned 
Okamura et 
al., 1992 
70%PH Hepatotrophic Inhibition of IL-2 
production 
Not mentioned 
Tanaka et al., 
1993 
70%PH Hepatotrophic Inhibition of IL-2 
production and binding 
Inhibition of NK 
cell responses 
Bendahan et 
al., 1994 
70%PH Return of the 
regenerative response 
to normal time scale 
Inhibition of IL-2 
production 
Not mentioned 
Escribano et 
al., 2002 
70%PH Promotion of liver 
regeneration 
Not mentioned Up-regulates 
insulin receptors 
in hepatocytes 
 
In contrast, little information is available regarding the effect of MMF and RAD on 
liver regeneration. Both are new drugs, introduced recently in clinical 
immunosuppressive regimen. The first report regarding the use of MMF in clinical 
liver transplantation dated from 1996 (McDiarmid, 1996), whereas RAD was only 
introduced in 1999 by Watson (Watson et al., 1999). Both drugs exert their 
immunosuppressive activity by blocking T lymphocyte proliferation (Brazelton and 
Morris, 1996). 
4.4.2.2 Animal model and experimental design 
The reason to select the four drugs with different mechanism was to evaluate how 
immune activation must be blocked in order to influence liver regeneration, either 
by inhibition of IL -2 production or by influencing the T cell response. 
As enhancement of liver regeneration using the standard liver resection model by 
calcineurin inhibitors has been observed in the past, the current study was 
designed using a model of subtotal hepatectomy, where the course of liver 
regeneration is altered.  
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4.4.2.3 Inhibition of immune activation and liver regeneration 
In the present study, both CsA and Fk506 had a slightly promoting effect on the 
survival rate. However, only the former one augmented liver regeneration 
significantly at 48 hours after subtotal PH. Proliferation was almost completely 
abrogated when using drugs blocking T-cell proliferation. 
4.4.2.3.1 Inhibition of immune activation by calcineurin inhibitors 
Calcineurin inhibitors act at an early stage after T cell receptor signalling by 
inhibiting calcineurin, a serine threonine phosphatase invo lved in the activation of 
transcription factors nuclear-factor-of-activated-T-cells (NFAT), nuclear factor 
kappa B (NF-kB) and activator protein-1 (AP-1), which induce the expression of 
several cytokines including IL -2 (Goddard and Adams, 2002).  
As mentioned before, it has been reported by different authors that liver 
regeneration is impaired in the presence of IL -2 and enhanced when the IL-2 
pathway is pharmacologically blocked. The underlying mechanism has not yet 
been revealed (Table 20). Our own observations:  firstly, the inhibition of 
regeneration in an immune activated animal, - with supposingly elevated IL-2 
levels-, and secondly, the increased proliferation rate in the CsA-treated rats, 
where IL -2 production is blocked, is supporting this concept.  
Although these results do not contribute to elucidating the mechanism, they are 
nevertheless of clinical importance. If immune activation by Hepatitis B vaccination 
is impairing regeneration as observed and if active hepatitis would exert a similar 
effect on regeneration, the use of small-for-size grafts should be critically 
discussed in patients with viral liver disease. One recent report describes that 
Lamivudine, an antiviral drug reducing viral replication and thus activity of the 
disease as indicated by a reduction in the necroinflammatory activity  (Suzuki 
1999), leads to rapid regeneration of the atrophic liver in decompensated cirrhosis 
due to hepatitis B (Saito et al., 2002), an observation which further supports the 
concept.  
4.4.2.3.2 Inhibition of immune activation by antiproliferative drugs 
Although MMF has already replaced Azathioprine in standard triple 
immunosuppressive protocols used in partial liver graft recipients nowadays 
(Gummert et al., 1999), up to now its influence on liver regeneration was not 
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addressed. Besides the inhibition effect on both T and B lymphocytes proliferation, 
recent evidence suggested that MMF is also capable of inhibiting the proliferation 
of non-immune cells, such as smooth muscle cells, renal tubular cells and 
mesangial cells (Morath and Zeier, 2003). The antiproliferative effect is mediated 
via the selective, non-competitive and reversible inhibition of inosine 
monophosphate dehydrogenase (IMPDH) and of the type II isoform in particular. 
IMPDH is the rate-limiting enzyme in the de novo biosynthesis of guanosine 
nucleotides.  
Up to now, only one group studied the effect of MMF on liver regeneration. In 
contrast to the results of this study, they observed an enhanced mitotic rate and a 
delayed, but increased peak in the TK activity in MMF-treated animals undergoing 
standard 70%PH. However, comparison between the two studies is hardly 
possible. They did not give any details regarding the kinetics of regeneration. They 
used a different surgical model and assessed regeneration using other parameters 
than in the present study. Before coming to a definite conclusion regarding the 
effect of MMF on hepatocyte proliferation, the time course of liver regeneration 
must be investigated in direct comparison to the other drugs.  
RAD, also known as Sirolimus, is causing  G1-phase cell cycle arrest by inhibition 
of the mammalian target of rapamycin, which is a downstream effector of the 
phosphatidylinositol 3-kinase / protein kinase B signalling pathway mediating cell 
survival and proliferation (Panwalkar et al., 2004). The antiproliferative effect of 
RAD is nowadays not only used to suppress immune activation but is also 
evaluated for inhibiting smooth muscle cell proliferation (McKeage et al., 2003) to 
prevent in-stent restenosis and, much more important,  to treat malignant growth.  
Some information is available on the effect of RAD on liver proliferation in vivo 
(Table 23). Francavilla observed the inhibitory effect of RAD not only on liver, but 
also on kidney as well as intestine regeneration (Francavilla et al., 1992). This 
observation was confirmed by Chavez in 1999, who stated that the hepatotrophic 
effect of cyclosporine and FK506 was not mimicked by RAD (Chavez et al., 1999). 
Jiang identified which signal transduction pathway was disrupted by RAD-
treatment explaining the inhibition of liver regeneration in a rat model of 70%PH 
(Jiang et al., 2001).  
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Table 23. Effect of RAD on liver regeneration  
Author/ 
Publish year Model 
Effect on liver 
regeneration Mechanism  
Francavilla et 
al., 1992 
70%PH Antihepatotrophic Not mentioned 
Chavez et al., 
1999 
70%PH Reduced regeneration Not mentioned 
Jiang et al., 
2001 70%PH 
Attenuation of 
regeneration 
Growth-suppressive effect due to 
dephosphorylation of p70 S6 kinase 
and/or 4E-BP1 
 
RAD acts directly on the proliferative capacity of the cells by inhibiting the cell 
cycle. The observed inhibition of liver regeneration might well be a direct effect of 
this drug via the above mentioned pathway. It seems that this effect is of much 
more biological relevance than the hypothesized liver growth promoting effect via 
the inhibition of T cell proliferation, even more as the key step in promoting or 
impairing regeneration by inhibition of immune activation seems to be related to 
the absence or presence of liver growth promoting cytokines.  
The clinical recommendation resulting from these studies is to restrict the use of 
both antiproliferative drugs when using small-for-size grafts, but to promote its use, 
especially of RAD, in cancer patients undergoing full size liver transplantation. In 
this situation a growth inhibitory effect would be rather beneficial for the patient.  
In summary, inhibition of immune activation by calcineurin inhibitors enhanced 
liver regeneration, possibly through the suppressed production of IL -2. The 
antiproliferative drugs inhibited T cell activation effectively, but seemingly also 
exerted a direct effect on proliferation of parenchymal cells, which explains the 
observed inhibitory effect on liver regeneration.  
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5 SUMMARY 
Introduction: Using a partial liver graft obtained from a living donor takes 
advantages of the unique capability of the liver to regenerate. This study aims to 
validate the immunohistochemical (IHC) assay to quantify liver regeneration, to 
investigate the kinetics of regeneration after transplantation and to study the  
negative feedback mechanism between immune activation and liver regeneration.  
Materials and Methods: Lewis rats were used as donors for the 30% partial liver 
grafts (POLT) and as recipients, as well as for 70% and 90% liver resection (PH).  
Kinetics of regeneration was compared after 70%PH and 30%POLT. The 
influence of prolonged ischemia was assessed by comparing the hepatocyte 
proliferation rate in liver grafts subjected to either 1h, 3h or 5h of cold ischemia. 
The influence of immune activation on liver regeneration was studied by subjecting 
the animals to hepatitis B vaccination prior 70%PH in comparison to the untreated 
hepatectomized rats. The effect of inhibition of immune activation was investigated 
by using either drugs suppressing IL-2 production (Calcineurin inhibitors CsA and 
FK506) or inhibiting T-cell proliferation (MMF and RAD). BrdU 50mg/kg was 
injected intravenously 1h prior to sacrifice. Paraffin embedded liver samples were 
used for IHC detection of the incorporated halogenated nucleotide.  
Results: Comparison between the conventional and computer-assisted 
quantification of the hepatocyte  nuclei revealed a strong correlation between the 
two methods (r=0.868). Intra- and Inter-assay variation were low (CV<10%), 
demonstrating the high precision of the assay. Regeneration following 70%PH 
peaked at day 1 postoperatively. Transplantation delayed the onset of liver 
regeneration by 24 hours. Prolonged ischemia reduced the maximal LI. Immune 
activation prior to 70%PH did not alter the kinetics of regeneration, but reduced the 
maximal proliferation rate, possibly related to the increased IL-2 secretion in 
response to vaccination. Inhibition of IL -2 production by calcineurin inhibitor 
tended to increase the proliferation rate, whereas the use of antiproliferative drugs 
blocked liver regeneration almost completely.  
Conclusions: Transplantation as well as prolonged ischemia postponed and 
impaired regeneration. The hypothesis regarding the immunological regulation of 
liver regeneration was supported, as immune activation inhibited regeneration and 
inhibition of IL-2 production by CsA enhanced the regeneration rate.  
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7 ABBREVIATIONS 
AP-1 – activator protein-1  
BrdU – bromodeoxyuridine 
CL – caudate lobe 
CsA – cyclosporin A 
CTL – cytotoxic T lymphocytes 
CV – coefficient of variance 
ELISA – enzyme-linked immunosorbent assay 
GRWR – graft-to-recipient weight ratio 
GSLV – graft-to-recipient standard liver volume ratio 
HCC – hepatocellular carcinoma 
IFN-gamma – interferon-gamma 
IHC – immunohistochemistry 
IMPDH – inosine monophosphate dehydrogenase  
IL-2 – interleukin-2 
IL-6 – interleukin-6 
LAK – lymphokine-activated killer cells 
LI – labeling index 
LEW – Lewis 
LDLT – living donor liver transplantation 
MHC – major histocompatibility complex 
MMF – Mycophenolate mofetil 
NAPOLT – non-arterialized partial orthotopic liver transplantation 
NFAT– nuclear-factor-of-activated-T-cells  
NK cells – natural killer cells 
NF-kB – nuclear factor kappa B  
NKT cells – natural killer T cells 
NOR – nucleolar organizer region 
ODC – ornithine decarboxylase 
PCNA – proliferating cell nuclear antigen 
PH – partial hepatectomy 
POD – postoperative day  
RAD – Sirolimus 
 
70 
RLI – inferior portion of the right lateral lobe 
RLS – superior portion of the right lateral lobe 
TK – thymidine kinase 
TNF-alpha –-tumor necrosis factor alpha  
UW – University of Wisconsin  
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